Serious Concerns Continue to Grow Over Use of HPV Drug GARDASIL
Since it's approval in the summer of 2006 by the Food and Drug Administration (FDA), 5 million girls and women, ages 9 to 26, have been vaccinated with GARDASIL.
GARDASIL, aggressively marketed by Merck & Co. Inc. with it's 'One Less' campaign, on television, radio, in print and on the internet, beginning in the fall of 2006, has been approved for distribution worldwide and is currently seeking approval for use in boys and men.
GARDASIL, manufactured by Merck & Co. Inc. and Cervarix, manufactured by Glaxo Smith Kline, have been the leading two drugs tested and approved for use in preventing the growth of specific human papillomaviruses (HPVs), by targetting 4 human papillomaviruses said to be responsible for the majority of HPVs found in the female population studied and now being vaccinated.
Of the 150 human papillomaviruses identified, 30 have been linked to cervical cancer.
According to the American Cancer Society, 90% of human papillomavirus infections are gone within two years, said to be true of the low risk HPVs and the high risk HPVs, said to cause cancer.
Claims that GARDASIL can prevent cervical cancer cannot be proven. Test subjects studied before the FDA approval of GARDASIL were not studied until the common age group for the appearance of cervical cancer in women, 35 to 55 years of age. For the girls and women vaccinated during the study, between the ages of 9 and 26, follow up study was less than 5 years.
The rate of cancer occurring in girls and women in the age group being vaccinated, ages 9 to 26, occurs at a rate of 20 to 30 in every 1 million girls and women, or less than several thousandths of 1 percent.
Heavy lobbying for making vaccination with GARDASIL mandatory for school aged girls in the U.S. has been the subject of debate and protest over the past two years, with many legislators with ties to the drug company being instrumental in trying to get passage of legislation in their states for the drug's use.
The National Vaccination Information Center (NVIC), a private parent led organization has collected data from emergency room visits. Of all the drug adverse reactions recorded after inoculation, GARDASIL has been 30 times higher.
From an article at CBSNews.com:
Gabby Swank was a straight-A student and cheerleader.
But that was before she became very ill following the standard dose of three Gardasil vaccinations, Attkisson reports.
You know the commercial. It showed teenage girls saying "I want to be one less" who gets the HPV virus, which is linked to cervical cancer.
"It was like a big hype among my friends, because we're like, 'we're gonna get it' because we felt almost pressured by the commercials," Gabby said.
Gabby got sicker after each shot, progressing to seizures, strokes and heart problems. It was her neurologist who suspected Gardasil was to blame.
"I think there are too many people having serious long-term side-effects," said neurologist Dr. Dwight Lindholm.
Last fall, the government and vaccine maker Merck concluded there's no link between Gardasil and serious adverse events like Gabby's. But a new analysis calls that finding into question.
During the production phase for the creation of both drugs, GARDASIL by Merck & Co. Inc. and Cervarix by Glaxo Smith Kline, a settlement agreement involving HPV gene patent infringement was settled with Merck & Co. Inc., makers of GARDASIL, agreeing to pay the makers of Cervarix, Glaxo Smith Kline, a percentage of Merck's sales of GARDASIL.
This agreement was meant to offset the early introduction of GARDASIL onto the drug market. Glaxo Smith Kline's drug, Cervarix, was introduced more than a year after Merck & Co. Inc.'s drug GARDASIL, with Glaxo Smith Kline stating that Merck & Co. Inc. had been instrumental in educating the public about HPVs and the need for vaccination against the viruses.
In 2008, the FDA refused approval of GARDASIL for use in women 27 to 46 years of age.
Click here to read the article.
Also at NowPublic: